For consideration of Rs 1827 cr
Panacea Biotec announced that the asset purchase agreement has been executed on 28 February 2022 for the sale of pharmaceutical formulation brands of the company's material subsidiary, Panacea Biotech Pharma in India and Nepal to Mankind Pharma for an aggregate consideration of Rs 1827 crore.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
